The healthcare landscape continues to evolve rapidly, with significant investments and regulatory actions shaping access to care and the technologies that deliver it. Recent developments, including a substantial funding round for social care platform Findhelp, latest investment in virtual care solutions, a major acquisition in healthcare navigation, and a warning from the Food and Drug Administration regarding telehealth practices, signal a period of both innovation and increased scrutiny. These changes are poised to impact millions of patients and healthcare providers across the United States.
On Tuesday, March 3, 2026, TPG, a leading global alternative investment management firm, announced a $250 million investment in Findhelp, the nation’s largest social care technology platform. This investment, made through The Rise Funds, TPG’s global impact investing platform, aims to expand access to essential services for underserved populations. Founded in 2010, Findhelp connects individuals with over 900,000 verified community program locations nationwide, serving over 800 customers including health systems, health plans, government agencies, and employers. The platform facilitates identifying social needs, connecting individuals to local services, managing care workflows, and measuring impact through analytics. Findhelp also streamlines benefits eligibility verification and enrollment for programs like Medicare and Medicaid.
Expanding the Social Safety Net Through Technology
The investment in Findhelp reflects a growing recognition of the critical role social determinants of health play in overall well-being. These determinants – factors like housing instability, food insecurity, and lack of transportation – significantly impact health outcomes. Addressing these needs often requires navigating complex systems and identifying appropriate resources, a process Findhelp aims to simplify. According to Erine Gray, Founder and CEO of Findhelp, the partnership with TPG will “accelerate growth, expand our national network, and invest more aggressively in our technology,” positioning the company to meet increasing demand from various stakeholders as social care becomes more integrated into mainstream healthcare delivery. The company’s platform helps organizations identify social needs, connect individuals to trusted local services, manage complex social care workflows, and measure impact through integrated analytics.
This investment isn’t occurring in a vacuum. There’s a broader trend of private equity firms recognizing the potential for both financial returns and social impact in the healthcare sector. TPG’s The Rise Funds specifically focuses on investments that generate positive social and environmental outcomes alongside financial gains. The firm’s commitment to Findhelp underscores the belief that technology can be a powerful tool for addressing systemic inequities in healthcare access. The $250 million investment will allow Findhelp to scale its operations and reach more individuals in need, potentially improving health outcomes and reducing healthcare costs in the long run.
Virtual Care Gains Momentum with KeyCare Funding
Alongside the investment in Findhelp, KeyCare, an Epic-based virtual care company, secured $27.4 million in funding. The funding will be used to scale their AI-powered virtual care solution for health systems. KeyCare’s platform integrates directly with Epic, a widely used electronic health record system, allowing for seamless data exchange and streamlined workflows. This integration is a key differentiator, as it reduces administrative burden and improves care coordination. The company focuses on providing virtual care services for a range of conditions, leveraging artificial intelligence to enhance efficiency and accuracy.
The rise of virtual care has been particularly pronounced in recent years, accelerated by the COVID-19 pandemic. Patients have increasingly embraced the convenience and accessibility of telehealth, and health systems are seeking ways to expand their virtual care offerings. KeyCare’s focus on integration with Epic positions it well to capitalize on this trend, as many large health systems already utilize Epic as their primary EHR. The company’s AI-powered approach also suggests a commitment to innovation and a desire to improve the quality and efficiency of virtual care delivery.
Quantum Health Acquires CirrusMD to Enhance Healthcare Navigation
Further consolidating the virtual care space, Quantum Health acquired CirrusMD, a physician-led virtual care provider. The acquisition aims to advance healthcare navigation with a focus on physician-led virtual care. Quantum Health specializes in employee-focused healthcare navigation, helping individuals navigate the complexities of the healthcare system and access appropriate care. CirrusMD provides virtual primary care and behavioral health services, delivered by a network of physicians.
This acquisition represents a strategic move by Quantum Health to expand its service offerings and provide a more comprehensive healthcare navigation experience. By integrating CirrusMD’s virtual care capabilities, Quantum Health can offer its clients a wider range of services, including virtual consultations, chronic condition management, and behavioral health support. The combination of Quantum Health’s navigation expertise and CirrusMD’s clinical capabilities could lead to improved patient engagement, better health outcomes, and reduced healthcare costs.
FDA Issues Warnings Regarding Compounded GLP-1s
In a separate but equally important development, the Food and Drug Administration (FDA) warned 30 telehealth companies against illegally marketing compounded versions of glucagon-like peptide-1 (GLP-1) medications. The FDA sent letters to these companies, citing concerns about false or misleading claims regarding the safety and efficacy of these products. GLP-1s, such as semaglutide and tirzepatide, are medications originally approved for the treatment of type 2 diabetes but have gained popularity for weight loss.
Compounded drugs are created by combining ingredients to create a customized medication, often in response to a specific patient need. However, the FDA does not evaluate compounded drugs for safety and efficacy in the same way it does for approved medications. The agency’s warning highlights the risks associated with obtaining compounded GLP-1s through unregulated telehealth channels. The FDA is concerned that these companies are making unsubstantiated claims about the benefits of these products and potentially exposing patients to harmful side effects. The agency emphasizes that patients should only obtain medications from licensed healthcare providers and pharmacies. The FDA’s action underscores the need for greater oversight of the rapidly growing telehealth industry and the importance of protecting patients from potentially dangerous practices.
Understanding the Risks of Compounded Medications
Compounding pharmacies must adhere to specific quality standards, but oversight can be less stringent than for manufacturers of FDA-approved drugs. This can lead to variations in potency, purity, and sterility, potentially posing risks to patient safety. The FDA’s warning serves as a reminder that compounded medications should only be used when a commercially available alternative is not suitable for a patient’s individual needs, and only under the supervision of a qualified healthcare professional. The agency provides resources on its website for patients and healthcare providers regarding compounded drugs, including information on potential risks and how to report adverse events. More information can be found on the FDA website.
These developments – the investment in Findhelp, the funding for KeyCare, the acquisition of CirrusMD, and the FDA’s warning – collectively paint a picture of a healthcare system in flux. Technology is playing an increasingly important role in expanding access to care and improving efficiency, but it also presents new challenges related to regulation and patient safety. The coming months will likely see further innovation and consolidation in the healthcare space, as companies seek to capitalize on the growing demand for virtual care and personalized medicine.
Looking ahead, the impact of these changes will depend on a number of factors, including regulatory policies, reimbursement models, and patient adoption. Continued investment in social care infrastructure, coupled with responsible innovation in virtual care, will be crucial for ensuring that all individuals have access to the high-quality, affordable healthcare they deserve. The FDA is expected to continue its scrutiny of telehealth practices, particularly regarding the marketing of compounded medications, to protect patients from potential harm. Further updates on these developments will be closely monitored and reported as they turn into available.